What happens when the first physician ever to serve as America's drug czar — the person who coordinated a $44 billion federal budget across 19 agencies, got naloxone over the counter, and helped cut overdose deaths from a projected 165,000 to 74,000 ahead of schedule — decides his next mission is using artificial intelligence to discover new drugs in weeks instead of decades, starting with a novel compound for opioid addiction itself? In this episode of the Trustcast Show, Zane Myers speaks with Dr. Rahul Gupta, former White House drug policy director and now chief medical officer at GATC Health, about the AI platform that analyzes 400 trillion data points simultaneously across safety, efficacy, and off-target effects to predict whether a drug molecule will succeed with over 90% accuracy — before companies spend hundreds of millions of dollars and years finding out the hard way. He explains how compound 1021, a novel opioid addiction treatment, was discovered by narrowing 80 brain targets to three in the prefrontal cortex using AI, combining those three assets into one molecule, and publishing the results in the Proceedings of the National Academy of Sciences. He also explains why Lloyd's of London entered an exclusive contract with GATC to build debt insurance products around their predictions. They also discuss why every failed drug is really just a drug waiting to succeed for a different disease, how AI can repurpose shelved molecules for conditions like ALS where patients are running out of time, why animal data fails as a proxy for human physiology and how that's driving the push to phase out animal testing in drug development, and what the FDA is now allowing that makes this the most important inflection point in the history of pharmaceutical discovery. Dr. Rahul Gupta is the former Director of the White House Office of National Drug Control Policy and Chief Medical Officer of GATC Health, an AI-powered drug discovery company. Connect with Dr. Rahul Gupta: gatchealth.com GATC Health Chapters 00:00 Introduction to Dr. Rahul Gupta 00:50 Why walk away from a $44 billion federal budget to build drugs with AI 01:12 One American dying every five minutes — the scale of what he inherited at the White House 02:52 West Virginia, the worst opioid crisis in America, and a 40% drop in overdose deaths 04:10 Getting naloxone over the counter and down to $20 a two-pack 06:41 From 165,000 projected deaths to 74,000 — ahead of schedule and under budget 08:49 Where AI is real in drug development and where it's still hype 09:02 Why 90% of discovered drugs fail and never reach market 10:30 The UC Irvine study — 3,000 molecules blinded and tested with over 92% predictive accuracy 12:00 Lloyd's of London entering an exclusive contract around GATC's predictions 14:17 What prevents a competitor from replicating this — the secret sauce 15:45 Why human data instead of animal data is the core differentiator 17:00 What happens when a phase two readout goes badly — can AI save the asset 18:35 Turning accidental drug discoveries into intentional ones at scale 19:00 The coming revolution in drug approval and regulatory frameworks 21:07 Why animal science fails to translate into human physiology and what NAMS means 23:03 FDA and EMA joint guidance on AI in drug development 23:59 If you have $10 million and one shot — how AI fits into your development plan 25:34 How a pharma company would actually work with GATC Health 27:49 How much of your team's time does this actually require 30:01 What happens in the first three weeks after handing GATC a molecule 31:30 Compound 1021 — how an AI-discovered opioid addiction treatment was born 33:16 What 400 trillion data points actually means in plain English 34:44 Running safety, efficacy, and off-target effects simultaneously #RahulGupta #GATCHealth #AIDrugDiscovery #OpioidCrisis #DrugCzar #Naloxone #TrustcastShow #BiotechAI #DrugDevelopment #Compound1021
No transcript available.
POWERED BY BLUBRRY
